Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Lanz, Lisa-Marie
Wick, Antje
Harting, Inga
Dettmer, Susan
Suwala, Abigail K.
Ketter, Ralf
Tabatabai, Ghazaleh https://orcid.org/0000-0002-3542-8782
Seliger, Corinna
Glas, Martin
Burger, Michael C. https://orcid.org/0000-0002-6927-0987
Timmer, Marco
Ringel, Florian A.
Mildenberger, Iris https://orcid.org/0009-0008-8825-4908
Schulz-Schaeffer, Walter J. https://orcid.org/0000-0001-5886-2322
Winkler, Frank https://orcid.org/0000-0003-4892-6104
König, Laila
Herold-Mende, Christel https://orcid.org/0000-0002-1915-745X
Eisenmenger, Andreas
Pfister, Stefan M. https://orcid.org/0000-0002-5447-5322
Renovanz, Mirjam
Bendszus, Martin
Sahm, Felix https://orcid.org/0000-0001-5441-1962
Platten, Michael https://orcid.org/0000-0002-4746-887X
Kessler, Tobias https://orcid.org/0000-0001-8350-7074
Funding for this research was provided by:
Deutsche Krebshilfe (70111980)
Deutsche Forschungsgemeinschaft (SFB 1389, SFB 1389, SFB 1389)
Bundesministerium für Bildung und Forschung (HIPO 2-K25 and 2-K32R)
Article History
Received: 8 February 2025
Accepted: 29 July 2025
First Online: 5 September 2025
Competing interests
: W.W. declares consulting fees from Enterome, GSK and Servier. He received trial support with drugs from Apogenix, Pfizer and Roche. The other authors declare no competing interests.